de Souza Stephan Pinheiro Macedo, Tobar Natalia, Frasson Fernanda, Perini Efrain Araujo, de Souza Carmino A, Delamain Marcia T, Ramos Celso Dario
Division of Nuclear Medicine, Department of Radiology, Faculty of Medical Sciences, University of Campinas (UNICAMP).
Nuclear and Energy Research Institute (IPEN).
Nucl Med Commun. 2021 Dec 1;42(12):1355-1360. doi: 10.1097/MNM.0000000000001465.
Isolated case reports mention the uptake of radiolabeled PSMA in lymphoma. However, it is not clear if the intensity of 68Ga-PSMA expression varies among different histological subtypes or if it correlates with 18F-FDG uptake. This study compared both tracers in patients with diverse lymphoma subtypes.
Ten patients with biopsy-proven-lymphoma underwent 18F-FDG and 68Ga-PSMA-PET/CT (maximum time interval: 6 days). Lymphoma subtypes included Hodgkin's lymphoma (HL, three patients) and aggressive and indolent non-Hodgkin's lymphoma (NHL, seven patients). The intensity of PSMA uptake was classified visually as low, intermediate, or high, using blood pool, liver and parotid gland uptake as references. Maximum standardized-uptake value (SUVmax) of each affected site was measured in both sets of images.
FDG detected 59/59 involved sites in 10 patients and PSMA 47/59 sites in nine patients. PSMA uptake was generally low, regardless of the intensity of FDG uptake, but it was classified as intermediate in two patients. The median SUVmax varied from 2.0 (2.0-8.2) to 30.9 for FDG and from 1.7 (1.7-1.7) to 4.4 for PSMA, P < 0.0001. The primary lesion of one patient had a marked intralesional mismatch uptake pattern of the tracers, with areas of higher PSMA expression than FDG uptake, and vice-versa. A brain lesion was more easily identified with PSMA than with FDG images.
HL and several NHL subtypes may present PSMA uptake. The intensity of PSMA expression is generally lower than that of FDG uptake and seems to present less variation among the different histological subtypes of lymphomas.
个别病例报告提及放射性标记的前列腺特异性膜抗原(PSMA)在淋巴瘤中的摄取情况。然而,尚不清楚68Ga-PSMA表达强度在不同组织学亚型之间是否存在差异,或者它是否与18F-氟代脱氧葡萄糖(18F-FDG)摄取相关。本研究比较了不同淋巴瘤亚型患者中这两种示踪剂的情况。
10例经活检证实为淋巴瘤的患者接受了18F-FDG和68Ga-PSMA正电子发射断层扫描/计算机断层扫描(PET/CT)(最大时间间隔:6天)。淋巴瘤亚型包括霍奇金淋巴瘤(HL,3例患者)以及侵袭性和惰性非霍奇金淋巴瘤(NHL,7例患者)。以血池、肝脏和腮腺摄取为参照,将PSMA摄取强度在视觉上分为低、中或高。在两组图像中测量每个受累部位的最大标准化摄取值(SUVmax)。
FDG在10例患者中检测到59个受累部位中的59个,PSMA在9例患者中检测到59个部位中的47个。无论FDG摄取强度如何,PSMA摄取通常较低,但有2例患者被分类为中等。FDG的SUVmax中位数为2.0(2.0 - 8.2)至30.9,PSMA的SUVmax中位数为1.7(1.7 - 1.7)至4.4,P < 0.0001。1例患者的原发灶在病灶内出现了明显的示踪剂摄取不匹配模式,PSMA表达高于FDG摄取的区域,反之亦然。与FDG图像相比,PSMA更容易识别脑部病变。
HL和几种NHL亚型可能存在PSMA摄取。PSMA表达强度通常低于FDG摄取,并且在淋巴瘤的不同组织学亚型之间似乎变化较小。